Keyphrases
Antineutrophil Cytoplasmic Antibody
100%
Remission
100%
Granulomatosis with Polyangiitis
100%
Microscopic Polyangiitis
100%
ANCA-associated Vasculitis
50%
Risk Factors
33%
Immunosuppressive Therapy
33%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
16%
Randomized Clinical Trial
16%
Early Detection
16%
Expert Opinion
16%
Chronic Disease
16%
Genetic Background
16%
Relapse Prevention
16%
Inflammatory Diseases
16%
Patient Management
16%
Disease Entity
16%
Limited Disease
16%
Medium-sized Vessel
16%
Maintenance Treatment
16%
Maintenance Therapy
16%
Renal Involvement
16%
Wegener
16%
Serial Measurements
16%
Early Prevention
16%
Churg-Strauss Syndrome
16%
Great Debates
16%
Patient Classification
16%
Therapeutic Decision-making
16%
Pulmonary Hemorrhage
16%
Area Cover
16%
Capillaritis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Wegener Granulomatosis
100%
Microscopic Polyangiitis
100%
Neutrophil Cytoplasmic Antibody
100%
ANCA Associated Vasculitis
66%
Immunosuppressive Agent
33%
Inflammatory Disease
16%
Lung Hemorrhage
16%
Chronic Disease
16%
Randomized Clinical Trial
16%
Churg Strauss Syndrome
16%
Eosinophilic Granuloma
16%
Capillaritis
16%
Diseases
16%
INIS
antibodies
100%
neutrophils
100%
patients
100%
therapy
50%
diseases
37%
risks
25%
maintenance
25%
detection
12%
validation
12%
mortality
12%
clinical trials
12%
morbidity
12%
reviews
12%
vessels
12%
hemorrhage
12%
inflammation
12%
kidneys
12%
management
12%
classification
12%
genetics
12%
Medicine and Dentistry
Granulomatosis with Polyangiitis
100%
Microscopic Polyangiitis
100%
Neutrophil Cytoplasmic Antibody
100%
ANCA Associated Vasculitis
66%
Immunosuppressive Treatment
33%
Maintenance Therapy
33%
Chronic Disease
16%
Randomized Clinical Trial
16%
Pulmonary Hemorrhage
16%
Inflammatory Disorder
16%
Genetic Background
16%
Churg-Strauss Syndrome
16%
Capillaritis
16%
Diseases
16%
Eosinophilic Granulomatosis with Polyangiitis
16%
Immunology and Microbiology
Granulomatosis with Polyangiitis
100%
Neutrophil Cytoplasmic Antibody
100%
Microscopic Polyangiitis
100%
ANCA Associated Vasculitis
66%
Immunosuppressive Therapy
33%
Inflammatory Disorder
16%
Genetic Background
16%
Patient Coding
16%
Churg-Strauss Syndrome
16%
Eosinophilic Granulomatosis with Polyangiitis
16%
Biochemistry, Genetics and Molecular Biology
Anti-Neutrophil Cytoplasmic Antibody
100%
Randomized Clinical Trial
14%
Genetic Background
14%
Patient Coding
14%